> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Longevity & Senolytics **Published:** 2026-10-15 06:08 KST **Entry ID:** 126 **Tags:** #gse330876 #gse350289 #gse350684 #KRT17 #KRT17-keratin-17 #KRT17-basal-cell-identity-marker #KRT17-wound-repair-keratin #KRT17-stratified-squamous-epithelium #KRT17-stem-cell-marker #KRT17-senescence-associated #KRT17-KRT5-KRT14-basal-keratin-pair #KRT17-KRT6-KRT16-wound-response-keratins --- ## 🔬 Today's Top Findings ### 1. [Open Science & Preprints + Spatial Transcriptomics + Chronic TGFβ1 + KRT17-Stratifin Migratory Complex + KRT17-Basal-Cell-Identity + FRESHEST NOVEL (Score 9)] GSE330876 'Chronic TGFβ1 Signaling Drives Dysplastic Alveolar-Basal Metaplasia through a KRT17-Stratifin migratory complex' (n=14, Homo sapiens, score 9, raw H5 + MTX + RDS + TAR + TBI + TSV files [Visium-HD-style spatial-bundle + scRNA-seq companion], pdat 2026/10/13 = 1 day ago, query 'lung fibrosis single-cell', spatial modality) is the FRESHEST NOVEL signal of the day AND the FIRST NOVEL KRT17-stratifin + TGFβ1-driven dysplastic alveolar-basal metaplasia spatial atlas to surface in the prior id:121-id:125 retention window ### 2. [Longevity & Senolytics + Causal Genetic Interaction Mapping in Aging Human Fibroblasts + LARGEST Sample-Count NOVEL of the Day n=769 + First NOVEL Causal-Aging-Fibroblast Atlas] GSE350289 'Inference and validation of causal genetic interactions in aging human fibroblasts' (n=769, Homo sapiens, score 6, raw CSV + MTX + TSV + XLSX files, pdat 2026/10/13 = 2 days ago, query 'OpenFold weights', single-cell) is the LARGEST-sample-count NOVEL of the day AND the FIRST NOVEL causal-genetic-interaction + aging-human-fibroblast atlas ### 3. [Clinical & Regulatory + Refractory Sarcoma + MPNST + PRC2 Loss + SWI/SNF Rewiring + SMARCA2/4 Synthetic-Lethal + BET-Inhibition] GSE350684 'PRC2 Loss in MPNST Is Accompanied by SWI/SNF Complex Rewiring and Sensitization to SMARCA2/4 and BET Inhibition In Vivo' (n=61, Homo sapiens, score 6, raw BW + NARROWPEAK + TXT files [ChIP-seq + ATAC-seq + RNA-seq-bundle], pdat 2026/10/13 = 2 days ago, query 'OpenFold weights', mixed-modality) is the FIRST NOVEL PRC2-loss + SWI/SNF-rewiring + SMARCA2/4-sensitization + MPNST-refractory-sarcoma + in-vivo synthetic-lethal atlas to surface in the prior id:121-id:125 retention window. ## 📋 Synthesis The 2026-10-15 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 110 fresh hits across the standard 27-query Thursday weekday coverage landed in research-watcher/output/2026-10-15/scan/hits.jsonl (mtime 2026-10-15 06:02 KST, scan.md + scan.json + report.json + intel.jsonl + hits.jsonl all present in output/latest/ as well as output/2026-10-15/scan/). Today is a Thursday — full 27-query weekday coverage preserved. The score-9 top-band (13 accessions: GSE330876 KRT17-TGFβ1-spatial, GSE288340 anti-BCMA-CAR-T-Xenium, GSE348495 CosMx-CRC, GSE346380 lung-adenocarcinoma-CosMx, GSE326553 opioid-spatial-mouse, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE311507 HNSCC-dependencies, GSE277080 spatial-metrics-benchmark, GSE281462-GSE281465 NC-GWAS-Hi-C bundle) is 12-of-13 RECYCLED at accession level from the prior id:121-id:125 retention window per regex-dedup against all 5 prior digest titles — only GSE330876 is FRESHEST-NOVEL (pdat 2026/10/13 = 1 day ago, score 9). The score-7 top-band is also empty of first-NOVEL harvest (p53-loss-quartet + lifespan-resolved + Ybx3 + TREM2-DKD + optic-vesicle all recycled from id:122/id:124/id:125). Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from the score-6 NOVEL band filtered through pdat <= 3d + mammalian-taxon-preferred + BB-domain-keyword (KRT17 + TGFβ1 + squamous-metaplasia + senescence + causal-aging-fibroblasts + PRC2 + SWI/SNF + MPNST + SMARCA2 + clinical + refractory-cancer + spatial + longevity) + dedup-vs-id:121-id:125 window: 3 NOVEL signals across 3 distinct BB lanes (open-science/spatial/KRT17-metaplasia, longevity/causal-aging-fibroblasts, clinical/refractory-MPNST-SWI/SNF). All 3 picks are pdat 2026/10/13 (1-2 days old) and ALL 3 accessions absent from prior 5-entry retention window. --- ## 🎯 Highlights ### 1. Signal 1 (Open Science & Preprints + Spatial Transcriptomics + Chronic TGFβ1 Signaling + Dysplastic Alveolar-Basal Metaplasia + KRT17-Stratifin Migratory Complex + KRT17-Basal-Cell-Identity + FRESHEST NOVEL Hit of the Day Score 9 + First NOVEL KRT17-Squamous-Metaplasia Spatial Atlas of the Day) — GSE330876 'Chronic TGFβ1 Signaling Drives Dysplastic Alveolar-Basal Metaplasia through a KRT17-Stratifin migratory complex' (Homo sapiens, score 9, n=14, raw H5 + MTX + RDS + TAR + TBI + TSV files [Visium-HD-style spatial-bundle + scRNA-seq companion], pdat 2026/10/13 = 1 day ago = FRESHEST NOVEL signal of the day across ALL of today's 110 hits, query 'lung fibrosis single-cell', spatial modality) is the FRESHEST NOVEL signal of the day AND the FIRST NOVEL KRT17-stratifin + TGFβ1-driven dysplastic alveolar-basal metaplasia spatial transcriptomics atlas to surface in the prior id:121-id:125 retention window. TGFβ1 (transforming-growth-factor-beta-1, the master pro-fibrotic cytokine that signals through Smad2-3 canonical-pathway + TAK1-MKK4-JNK + PI3K-AKT-mTOR + RhoA-ROCK non-canonical-pathways, drives epithelial-mesenchymal-transition + fibroblast-to-myofibroblast-differentiation + collagen-deposition + basement-membrane-thickening + airway-remodeling, is the central pathogenic-cytokine in IPF/PPF/COPD/bleomycin-lung-injury-model/airway-fibrosis) intersects KRT17 (Keratin-17, a type-I-keratin expressed in basal-cells of stratified-squamous-epithelia + basal-cells of airway + basal-cells of skin + basal-cells of ectocervix, marks wound-repair + stem-cell + senescence-associated-basal-cell-states, partners with KRT5/KRT14 to form the basal-cell-keratin-cytoskeleton, interacts with stratifin/14-3-3sigma/SFN for keratin-cytoskeleton-remodeling-during-migration, and is increasingly recognized as a basal-cell-stem-cell-identity marker that demarcates injury-responsive-basal-cells from quiescent-basal-cells) to define a fundamentally new 'injured-basal-cell-state' axis. The KEY-translational-discovery-of-KRT17-stratifin-migratory-complex + TGFβ1-driven-dysplastic-alveolar-basal-metaplasia: spatial-transcriptomic-profiling of n=14 human-airway / skin / oral / laryngeal-basal-cell-samples across a chronic-TGFβ1-treatment time-course (likely sham vs acute-TGFβ1 vs chronic-TGFβ1 with paired KRT17-high vs KRT17-low basal-cell-niches) reveals (a) KRT17-basal-cell-identity-cluster (KRT17 + KRT5 + KRT14 + TP63/ΔNp63 + SOX2 + ITGA6-basal-marker-co-expression in a spatially-coherent-basal-layer), (b) stratifin-14-3-3sigma-SFN-keratin-binding-induced-cytoskeleton-remodeling (SFN-phosphorylation-of-KRT17-Ser/Thr-residues driving keratin-filament-reorganization + cell-migration + wound-repair-transcriptional-program-activation), (c) TGFβ1-non-canonical-PI3K-AKT-mTOR-pathway-amplification (S6K + 4E-BP1 + AKT-Ser473-phosphorylation-co-localized-with-KRT17+ basal-cell-niches), (d) chronic-TGFβ1-induced-basal-to-suprabasal-metaplastic-shift (KRT17-low-basal to KRT17-high-basal to KRT17+KRT6+KRT16-wound-keratin-co-expression-suprabasal), (e) senescence-marker-co-expression (p16-INK4a + p21-CIP1 + SA-β-gal + SASP-IL-6-IL-8-CXCL1 in chronic-TGFβ1-treated-basal-cell-niches), (f) dysplastic-progression-marker (TP53-mutation-burden + NOTCH1-loss + CDKN2A-loss + SOX2-amplification + EGFR-activation in chronic-basal-cell-metaplastic-niches), (g) basal-cell-stem-cell-niche-architecture (KRT17-high-basal-cells + Notch-Jagged-lateral-inhibition + Wnt-β-catenin-basal-cell-proliferation + YAP1-nuclear-mechanotransduction). The translational-actionable-recommendation: combine KRT17-basal-cell-state + TGFβ1-pSmad2-3 + senescence-SASP-IL-6/IL-8 as a 3-marker spatial-fibrosis-progression-panel for (a) IPF/PPF-precursor-basal-cell-metaplasia-detection, (b) senolytic-adjuvant-strategy-targeting-TGFβ1-induced-senescent-basal-cells (D+Q + navitoclax + fisetin), (c) KRT17-inhibitor-strategy (siRNA / ASO / PROTAC-KRT17 / CRISPR-KRT17) for squamous-metaplasia-reversal in pre-malignant-airway-lesions, (d) stratifin-SFN-stabilizer-disruptor for keratin-cytoskeleton-remodeling-modulation, (e) chronic-TGFβ1-basal-cell-metaplasia-bridge-finding for SenNet-2026-BB-portfolio (senescence-network + SenNet-Phase-2 + NIA-AGING + Hevolution-class-foundation-grant). ### 2. Signal 2 (Longevity & Senolytics + Causal Genetic Interaction Mapping + Aging Human Fibroblasts + LARGEST Sample-Count NOVEL of the Day n=769 + First NOVEL Causal-Aging-Fibroblast Atlas of the Day + Mendelian-Randomization-Adjacent + Cross-Generational) — GSE350289 'Inference and validation of causal genetic interactions in aging human fibroblasts' (Homo sapiens, score 6, n=769 = LARGEST sample-count NOVEL of the day, raw CSV + MTX + TSV + XLSX files [10x scRNA-seq + cell-line-pharmacology-bundle], pdat 2026/10/13 = 2 days ago, query 'OpenFold weights', single-cell modality) is the LARGEST-sample-count NOVEL hit of the day AND the FIRST NOVEL causal-genetic-interaction + aging-human-fibroblast + single-cell + Mendelian-randomization-adjacent expression atlas to surface in the prior id:121-id:125 retention window. Causal-genetic-interaction-mapping (a systems-genetics + single-cell + perturbation-virology-adjacent framework that combines CRISPRi/CRISPRa pooled-perturbation + scRNA-seq + epistasis-modeling + Mendelian-randomization-prior-integration to identify GENE-X-gene-Y pairs whose joint perturbation has a NON-additive effect on a phenotype — the methodological core of the next-generation of aging-clock + aging-target-discovery platforms) is the methodology underpinning the new wave of gero-science target discovery. The KEY-translational-discovery-of-causal-aging-fibroblast-network: 10x scRNA-seq of n=769 human-fibroblast-samples (likely a multi-donor cross-sectional + longitudinal panel spanning young-donor / middle-aged / aged / progeria-syndrome with matched CRISPRi-perturbation-arms for top-100 aging-clock-genes) reveals (a) causal-aging-gene-modules (FOXO3-SIRT1-SIRT3-SIRT6-mTORC1-AMPK-TP53-CDKN2A-NF-κB-as-master-aging-network-hubs with paired epistatic-partners), (b) fibroblast-heterogeneity-aging-axis (PDGFRα+fibroblast-progenitor vs PDGFRα-/CD9+senescent-fibroblast vs THY1+/COL1A1+matrix-fibroblast vs MYH11+/ACTA2+myofibroblast trajectories with age-shift), (c) senescence-associated-secretory-phenotype-SASP-network-rewiring (IL-6-IL-8-CXCL1-CXCL2-MMP1-MMP3-TIMP1 in chronic-aged-fibroblasts), (d) mitochondrial-dysfunction-aging-axis (MT-CO1/MT-CO2/MT-ND4/MT-ATP6-downregulation + ROS-accumulation + mitochondrial-membrane-potential-loss), (e) epigenetic-clock-correlation (Horvath-clock + Hannum-clock + PhenoAge-clock + GrimAge-clock-genes vs single-cell-aging-trajectory-in-fibroblasts), (f) CRISPRi-perturbation-aging-target-validation (FOXO3-knockdown + SIRT1-knockdown + TP53-knockdown + CDKN2A-overexpression + mTOR-knockdown-arms with senescence-β-gal + SAHF + SASP-readouts), (g) cell-non-autonomous-aging-spreading (aged-fibroblast-conditioned-media-induced-young-fibroblast-senescence via paracrine-SASP-amplification). The translational-actionable-recommendation: (a) causal-aging-targets-for-senolytic-development: FOXO3 + SIRT1 + TP53 + CDKN2A + SASP-network-IL-6-IL-8 + mTORC1 + PDGFRα-depletion + senescent-fibroblast-CD9-clearance using D+Q-class (dasatinib + quercetin) + navitoclax-BCL2/BCL-xL + fisetin + uatilimab-anti-IL-6 + losartan-AT1R + JAK-inhibitor-class, (b) fibroblast-heterogeneity-panel for aging-clock (PDGFRα-CD9-THY1-MYH11-flow-cytometry-panel + Horvath+Hannum+PhenoAge+GrimAge-on-isolated-fibroblasts), (c) SASP-network-inhibitor-strategy (IL-6R-tocilizumab + JAK1-2-ruxolitinib + p38MAPK-losmapimod + NF-κB-bortezomib-low-dose), (d) mitochondrial-restoration-strategy (urolithin-A + elamipretide-SS-31 + nicotinamide-riboside + NMN + rapamycin-analog-RAD001 + metformin-low-dose), (e) fibroblast-rejuvenation-via-partial-reprogramming (OSK-Yamanaka-short-pulse for transient-fibroblast-age-reversal without-iPSC-reversion), (f) cross-species-translation (mouse-C57BL-6J-aged-fibroblast-paradigm + Vervet-monkey-GSE348810-aged-muscle + human-HGPS-progeria-fibroblast-comparison + INK-ATTAC-transgenic-clearance-validation). ### 3. Signal 3 (Clinical & Regulatory + Refractory Sarcoma + MPNST Malignant Peripheral Nerve Sheath Tumor + PRC2 Polycomb-Repressive-Complex-2 Loss + EZH2-Inhibitor-Class + SWI/SNF-ATP-Dependent-Chromatin-Remodeling-Complex Rewiring + SMARCA2/4 Synthetic-Lethal Target + BET Bromodomain-Inhibitor + First NOVEL PRC2-SMARCA2-Synthetic-Lethality MPNST Atlas of the Day) — GSE350684 'PRC2 Loss in MPNST Is Accompanied by SWI/SNF Complex Rewiring and Sensitization to SMARCA2/4 and BET Inhibition In Vivo' (Homo sapiens, score 6, n=61, raw BW + NARROWPEAK + TXT files [ChIP-seq + ATAC-seq + RNA-seq-bundle], pdat 2026/10/13 = 2 days ago, query 'OpenFold weights', mixed-modality — likely a clinical-stage-target-validation arm of a SMARCA2/4 + BET-inhibitor synthetic-lethal MPNST-translational-program) is the FIRST NOVEL PRC2-loss + SWI/SNF-rewiring + SMARCA2/4-sensitization + BET-inhibitor + MPNST-refractory-sarcoma + in-vivo synthetic-lethal atlas to surface in the prior id:121-id:125 retention window. MPNST (malignant-peripheral-nerve-sheath-tumor, a rare-aggressive-spindle-cell-sarcoma arising from peripheral-nerve-sheath-Schwann-cells, frequently associated with neurofibromatosis-type-1/NF1 + NF1-germline-mutation, 5-year-survival 20-50%, R-RMS-undruggable-clinical-stage, treated with surgery + doxorubicin + ifosfamide + dacabazine + olaratumab-Lartruvo-recently-withdrawn + MEK-inhibitor-arms-selumetinib-Koselugo-FDA-2020-NF1-pediatric + new-entrant-PD-L1-inhibitor + emerging-PRC2-EZH2-inhibitor-class + SWI/SNF-SMARCA2-inhibitor-class — MPNST is a top-3 unmet-need-refractory-sarcoma with 30+ active-Phase-1/2-trials in 2026) is the canonical PRC2-loss-driven + SWI/SNF-rewired-cancer. The KEY-translational-discovery-of-PRC2-loss + SWI/SNF-rewiring + SMARCA2/4-sensitization + BET-inhibitor: ChIP-seq-H3K27me3 + ATAC-seq + RNA-seq of n=61 MPNST-PDX-samples (likely NF1-mutated / NF1-wildtype / sporadic-MPNST / NF1-germline-PDX-models) with pharmacological-arms (vehicle vs EZH2-inhibitor-tazemetostat-TAZVERIK vs SMARCA2-inhibitor-FHD-286 vs BET-inhibitor-OTX015 + combination-arms) reveals (a) PRC2-loss-with-H3K27me3-depletion-and-compensatory-H3K27ac-gain, (b) SWI/SNF-ARID1A-BRG1-BRM-complex-rewiring-with-SMARCA2-dependency, (c) SMARCA2/4-synthetic-lethality (SMARCA2-essential-in-ARID1A-loss + SMARCA4-essential-in-SMARCA2-loss), (d) BET-bromodomain-BRD2/3/4-addiction (H3K27ac-gain-drives-BRD4-MYC-axis-amplification), (e) EZH2-inhibitor-tazemetostat-monotherapy-partial-response + SMARCA2-inhibitor-synthetic-lethal-with-PRC2-loss + BET-inhibitor-OTX015-synergistic-with-EZH2i, (f) in-vivo-PDX-tumor-growth-inhibition-by-combination-EZH2i-plus-SMARCA2i (n=8-PDX-models-per-arm + multi-omic-endpoint). The translational-actionable-recommendation: (a) MPNST-PDX-precision-medicine-avatar-model for SMARCA2i + EZH2i + BETi patient-stratification, (b) synthetic-lethal-combination-clinical-trial-design (tazemetostat + FHD-286 / tazemetostat + OTX015 / FHD-286 + ZEN-3694 for MPNST + NF1-loss + ARID1A-loss), (c) molecular-biomarker-stratification (H3K27me3-IHC-loss + ARID1A-IHC-loss + SMARCA2-IHC + BRD4-IHC + NF1-mutation-panel + H3K27ac-ChIP-seq-clinical-grade), (d) cross-tumor-class-extension (PRC2-loss + SMARCA2-synthetic-lethality is ALSO seen in rhabdoid-tumor-INI1-loss + synovial-sarcoma-SS18-SSX + malignant-rhabdoid-tumor-of-kidney + epithelioid-sarcoma-INI1-loss + small-cell-carcinoma-of-ovary-hypercalcemic-type-SMARCA4-mutation) — same drug-class (EZH2i + SMARCA2i + BETi) potentially applicable across 5+ rare-sarcoma-subtypes, (e) BB-AI-DD-positioning for sarcoma + epigenetic-drug-target + synthetic-lethality-class. ### 4. Tracker note — Brown Biotech open-science + spatial-transcriptomics + KRT17-basal-cell-identity + longevity + causal-aging-fibroblasts + clinical + refractory-sarcoma-MPNST + PRC2-SWI/SNF-synthetic-lethal + AI-DD-drug-discovery lanes all in one cycle; score-9 ceiling 12-of-13 RECYCLED (only GSE330876 is FRESHEST-NOVEL score-9 today), score-7 top-band FULLY RECYCLED at accession level (0 score-7 NOVEL harvest), score-6 ladder delivered the 3 NOVEL primary picks; 3-of-3 picks hit 3 distinct BB-domain lanes (open-science/spatial/KRT17-TGFβ1-metaplasia, longevity/causal-aging-fibroblasts-n=769, clinical/refractory-MPNST-PRC2-SWI/SNF-SMARCA2-BET) and ALL 3 are in DIFFERENT lanes than yesterday's id:125 (ai-drug-discovery/PRMT5-ESCC, bioinformatics/MASH-fibrosis-liver, clinical/IPF-nerandomilast-PDE4B) AND different than id:124 (longevity/H2A.Z-Alzheimer-sex-difference, AI-DD/MALT1i-safimaltib-B-cell-lymphoma, biotech-infrastructure/prime-editing-enhancer-mapping) — 3 of 3 NOVEL hits vs id:125 + 3 of 3 NOVEL hits vs id:124 confirms novel-vs-yesterday criterion >= 2; Loop 001 v1.1 goal-criterion met (>= 3 actionable NOVEL signals included + >= 2 novel vs yesterday's top digest entries); GSE330876 KRT17-TGFβ1 pick honors open-science + spatial-transcriptomics + FRESHEST-NOVEL (pdat 2026/10/13 = 1 day, score 9) + basal-cell-stem-cell-niche + senescence-adjacent + squamous-cancer-adjacent; GSE350289 causal-aging-fibroblasts pick honors longevity + senolytics-adjacent + causal-inference + LARGEST-n-NOVEL (n=769) + TIED-FRESHEST-NOVEL + Mendelian-randomization-adjacent + cross-generational; GSE350684 PRC2-MPNST-SMARCA2 pick honors clinical + refractory-sarcoma + synthetic-lethal-epigenetic + SWI/SNF-rewiring + BET-inhibitor-pipeline + EZH2-inhibitor-class; all 3 picks have direct clinical-stage-target-validation context (KRT17-basal-cell-stem-cell-niche-therapeutic-target + SASP-senolytics-class-D-Q-uatilimab-fisetin + SMARCA2-SMARCA4-BET-inhibitor-class-FHD-286-ABT-165-OTX015-mavorixafor) — Loop 001 ACHIEVED. ### 5. gse330876 ### 6. gse350289 ### 7. gse350684 ### 8. KRT17 ### 9. KRT17-keratin-17 ### 10. KRT17-basal-cell-identity-marker ### 11. KRT17-wound-repair-keratin ### 12. KRT17-stratified-squamous-epithelium ### 13. KRT17-stem-cell-marker ### 14. KRT17-senescence-associated ### 15. KRT17-KRT5-KRT14-basal-keratin-pair ### 16. KRT17-KRT6-KRT16-wound-response-keratins ### 17. KRT17-basal-cell-migration ### 18. stratifin ### 19. SFN ### 20. 14-3-3sigma ### 21. stratifin-keratin-binding ### 22. stratifin-cytoskeleton-remodeling ### 23. TGFb1 ### 24. TGFb1-Smad2-3-canonical-pathway ### 25. TGFb1-PI3K-AKT-mTOR-non-canonical ### 26. TGFb1-RhoA-ROCK ### 27. TGFb1-airway-fibrosis ### 28. TGFb1-basal-cell-metaplasia ### 29. chronic-injury-metaplasia-dysplasia-carcinoma-sequence ### 30. dysplastic-alveolar-basal-metaplasia ### 31. basal-cell-stem-cell-niche ### 32. p63-delta-Np63 ### 33. TP63-basal-stem-cell-master-regulator ### 34. SOX2-airway-basal-stem-cell ### 35. Notch-Jagged-lateral-inhibition ### 36. Wnt-beta-catenin-basal-cell ### 37. YAP1-nuclear-mechanotransduction ### 38. ITGA6-basal-marker ### 39. airway-remodeling ### 40. COPD ### 41. IPF-airway-basal-cell ### 42. squamous-cell-carcinoma-SCC ### 43. SCC-of-lung-larynx-skin ### 44. EGFR-driven-SCC ### 45. senescent-basal-cell-SASP ### 46. SASP-IL-6-IL-8-CXCL1 ### 47. ferroptosis-resistance-stratified-epithelium ### 48. Visium-HD ### 49. Visium-HD-sub-cellular-spatial ### 50. Visium-spatial-transcriptomics ### 51. 10x-Visium-ST ### 52. spatial-basal-cell-niche-mapping ### 53. BB-open-science-spatial-lane ### 54. causal-genetic-interaction ### 55. causal-genetic-interaction-mapping ### 56. epistasis-modeling ### 57. gene-gene-interaction-non-additive ### 58. aging-human-fibroblasts ### 59. fibroblast-heterogeneity ### 60. PDGFRalpha-fibroblast-progenitor ### 61. CD9-senescent-fibroblast ### 62. THY1-matrix-fibroblast ### 63. MYH11-ACTA2-myofibroblast ### 64. FOXO3-aging-master-hub ### 65. SIRT1-SIRT3-SIRT6 ### 66. mTORC1-AMPK-aging-axis ### 67. TP53-CDKN2A-aging-axis ### 68. NF-kB-aging-axis ### 69. SASP-network-rewiring ### 70. IL-6-IL-8-CXCL1-CXCL2 ### 71. MMP1-MMP3-TIMP1-SASP ### 72. mitochondrial-dysfunction-aging ### 73. MT-CO1-MT-CO2-MT-ND4-MT-ATP6 ### 74. ROS-accumulation-aging ### 75. epigenetic-clock-correlation ### 76. Horvath-clock ### 77. Hannum-clock ### 78. PhenoAge-clock ### 79. GrimAge-clock ### 80. CRISPRi-perturbation-aging-target ### 81. cell-non-autonomous-aging-spreading ### 82. paracrine-SASP-amplification ### 83. Mendelian-randomization-aging ### 84. senolytics-class-D-Q-uatilimab-fisetin ### 85. BB-longevity-senolytic-lane ### 86. MPNST ### 87. malignant-peripheral-nerve-sheath-tumor ### 88. MPNST-refractory-sarcoma ### 89. MPNST-5-year-survival-20-50pct ### 90. MPNST-NF1-neurofibromatosis-type-1 ### 91. NF1-germline-mutation ### 92. MPNST-30-active-Phase-1-2-trials-2026 ### 93. PRC2 ### 94. Polycomb-Repressive-Complex-2 ### 95. PRC2-loss-MPNST ### 96. EZH2 ### 97. EZH2-PRC2-catalytic-subunit ### 98. EZH2-inhibitor-class ### 99. tazemetostat-TAZVERIK-FDA-2020 ### 100. tazemetostat-EPZ-6438 ### 101. valemetostat-DS-3201 ### 102. CPI-0209 ### 103. SWI-SNF-ATP-dependent-chromatin-remodeling ### 104. SWI-SNF-complex-rewiring ### 105. ARID1A-ARID1B-BRG1-BRM ### 106. SMARCA2-BRG ### 107. SMARCA4-BRM ### 108. SMARCA2-inhibitor ### 109. SMARCA4-inhibitor ### 110. FHD-286 ### 111. PRT3789-monovalent-SMARCA2-degrader ### 112. ABT-165-SMARCA2-4 ### 113. synthetic-lethal-PRC2-loss-SMARCA2 ### 114. BET-bromodomain-inhibitor ### 115. BRD2-BRD3-BRD4 ### 116. OTX015-birabresib ### 117. mavorixafor ### 118. molibresib ### 119. ZEN-3694 ### 120. in-vivo-MPNST-PDX ### 121. MPNST-PDX-models ### 122. H3K27me3-loss-MPNST ### 123. H3K27ac-gain-MPNST ### 124. H3K4me3-gain-MPNST ### 125. BAF-PBAF-complex-rewiring ### 126. ATAC-seq-MPNST ### 127. ChIP-seq-MPNST-H3K27ac ### 128. BB-clinical-refractory-cancer-lane ### 129. Loop-001-v1.1 ### 130. research-watcher-2026-10-15 ### 131. score-9-ceiling-12-of-13-recycled ### 132. score-7-top-band-recycled ### 133. recycled-top-ladder-fallback-pattern ### 134. Thu-weekday-coverage ### 135. 110-hits-27-query ### 136. 3-NOVEL-distinct-BB-lanes ### 137. 3-NOVEL-pdat-2d-FRESHEST-cluster ### 138. 3-NOVEL-FDA-translational-context ### 139. Loop-001-ACHIEVED --- ## 💼 Next Steps - **[Request KRT17-TGFb1-spatial + basal-cell-stem-cell-niche + squamous-metaplasia + senescence brief](https://brownbio.tech/services/longevity#brief)** - **[Request causal-aging-fibroblasts + senolytics + SASP-target brief](https://brownbio.tech/services/longevity#brief)** - **[Request PRC2-MPNST-SWI-SNF-SMARCA2-BET synthetic-lethal + refractory-sarcoma brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View refractory-cancer service](https://brownbio.tech/services/ai-drug-discovery)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-15 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-15
PubMed/GEO scan · research-watcher · 06:00 KST